A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 12, 2011, Pages 1395-1399

  Sterman, Daniel H ^a   Haas, Andrew ^a   Moon, Edmund ^a   Recio, Adriana ^a   Schwed, Daniel ^a   Vachani, Anil ^a   Katz, Sharyn I ^a   Gillespie, Colin T ^a   Cheng, Guanjun ^a   Sun, Jing ^a   Papasavvas, Emmanouil ^b   Montaner, Luis J ^b   Heitjan, Daniel F ^a   Litzky, Leslie ^a   Friedberg, Joseph ^a   Culligan, Melissa ^a   June, Carl H ^a   Carrolly, Richard G ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

Clinical trials; Gene therapy; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; FLUORODEOXYGLUCOSE F 18; MESOTHELIN; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CELL CULTURE; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MALIGNANT PLEURAL MESOTHELIOMA; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MALE; MESOTHELIOMA; MIDDLE AGED; PILOT PROJECTS; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECOMBINANT PROTEINS;

EID: 80455172724     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0554CR     Document Type: Article

References (18)

1. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10:266-283. (Pubitemid 41025602)
2. Albelda S.M, Sterman D, Litzky L. Malignant mesothelioma. In: Fishman AP, editor. Pulmonary diseases and disorders, 4th ed. New York: McGraw-Hill; 2008. pp. 1535-1552.
3. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, Van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-147.
4. Sterman DH, Gillespie CT, Carroll R, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, et al. Interferon-beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Oncol 2006;3:633-663.
5. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-4466. (Pubitemid 47219714)
6. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18: 852-860.
7. Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007;2:265-267. (Pubitemid 47181706)
8. Demers GW, Sugarman BJ, Beltran JC,Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC. Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002;180:36-42. (Pubitemid 34293504)
9. Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009;72:936-944.
10. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55. (Pubitemid 32155814)
11. Zhang X, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFN-α infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells; further evidence for a strong bystander effect. Cancer Gene Ther 2008;15:817-822.
12. Da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, Whitty A, Hochman PS. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b vs. INF-β1a: understanding the functional relationship between distinct type 1 interferons that act through a common receptor. J Interferon Res 2002;22:173-188. (Pubitemid 34275485)
13. Fleischmann CM, Fleischmann WRJ. Differential antiproliferative activities of INFs alpha, beta and gamma: kinetics of establishment of their antiproliferative effects and the rapid development of resistance to INFs alpha and beta. J Biol Regul Homeost Agents 1988;2:173-185. (Pubitemid 19166925)
14. Jaitin DA, Roisma LC, Jaks E, Gavutis M, Piehler J. Inquiring into the differential action of interferons: an IFN-α2 mutant with enhanced affinity to INFAR1 is functionally similar to INF-β. Mol Cell Biol 2006;26:1888-1897.
15. Platanias LC, Uddin S, Domanski P, Colamonici OR. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type 1 interferon receptor. J Biol Chem 1996;271:23630-23633.
16. Delong P, Tanaka T, Kruklitis R, Henry A, Kapoor V, Kaiser LR, Sterman DH, Albelda SM. Use of cycloxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-7852. (Pubitemid 37466718)
17. Haas A, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, Albelda M. Cyclooxygenase-2 Inhibition augments efficacy of a cancer vaccine. Clin Cancer Res 2006;12:214-222. (Pubitemid 43166197)
18. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM. Chemotherapy delivered after viral immuno-gene therapy augments anti-tumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010;18:1947-1959.